Dr Reddy's has highlighted a number of positive trends underpinning business growth in its financial report for the second quarter of its 2010-11 fiscal year.
The generic pharmaceutical specialist reported a consolidated revenue figure of 18.7 billion rupees (264.7 million pounds), two percent ahead of last year's second quarter figure, while gross profits advanced by 15 percent in the same time frame.
Of this total, 13.7 billion rupees were contributed by its global generics segment, which grew by eight percent year-on-year, thanks to the contributions from branded generics markets.
Dr Reddy's launched 41 products in this category in Q2 2010, while 21 new product registrations and 13 drug master files were submitted during this period.
Earlier this month, the company announced that it has received approval from healthcare sector regulators in the US for the launch of a bioequivalent generic version of Takeda's Prevacid.
It has subsequently introduced its lansoprazole delayed-release capsules in US markets.